November 26, 2014 3:19 PM ET

Pharmaceuticals

Company Overview of Urigen Pharmaceuticals, Inc.

Company Overview

Urigen Pharmaceuticals, Inc., a development stage company, engages in the development and commercialization of therapeutic products for patients with urological disorders in North America. Its clinical stage product includes URG101, a bladder instillation for bladder pain syndrome/intersticial cystitis for men and women. The company is based in Wilmington, Delaware.

501 Silverside Road

PMB #95

Wilmington, DE 19809

United States

2 Employees

Phone:

925-280-2861

Fax:

925-280-2861

Key Executives for Urigen Pharmaceuticals, Inc.

Chairman
Age: 50
Scientific Founder
Age: 70
Co-Founder and IP Counsel
Compensation as of Fiscal Year 2014.

Urigen Pharmaceuticals, Inc. Key Developments

Imprimis Pharmaceuticals, Inc. Enters into License Agreement with Urigen Pharmaceuticals, Inc. for Patented Urology Formulation

Imprimis Pharmaceuticals, Inc. announced that it has entered into a license agreement, under which Imprimis acquired the US rights to commercially compound a patented combination of alkalized lidocaine and heparin from Urigen Pharmaceuticals, Inc. Physicians in the US and abroad have been prescribing and instilling this compounded drug formulation in different dosages to treat individual patients suffering from interstitial cystitis, also known as painful bladder syndrome (IC/PBS). Under the terms of the agreement, Imprimis shall pay Urigen tiered royalties based on net product sales with a minimum annual payment per unit for each prescription dispensed. The license does not require any cash payment by Imprimis upon execution. The license is non-exclusive for a period of six months, at which time Imprimis has the sole right to convert to an exclusive license. Once converted to an exclusive license, Imprimis is obligated to make certain annual minimum payments. The license is for the US market only and covers certain US patent rights that extend through 2026. The agreement contains provisions for the parties to remain long-term partners throughout the product lifecycle.

Urigen Pharmaceuticals Raises $750,000 Debt Financing

Urigen Pharmaceuticals raised $750,000 in a debt financing, according to documents filed with the Securities & Exchange Commission. The Wilmington, Del., specialty pharmaceutical company specializes in the developing products for patients with urological ailments such as painful bladder syndrome, urethritis, nocturia and over active bladder. Urigen's lead new drug candidate, the experimental painful bladder syndrome treatment URG101, is a proprietary combination of approved drugs that is instilled into the bladder. The company was seeking to raise $1 million.

Similar Private Companies By Industry

Company Name Region
InfaCare Pharmaceutical Corporation United States
Quigley Pharma, Inc. United States
Aurogen Incorporated United States
Merz Aesthetics, Inc. United States
Plexxikon Inc. United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
May 27, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Urigen Pharmaceuticals, Inc., please visit www.urigen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.